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Before the characterization of human and animal models of estrogen deficiency, estrogen action was confined in the context of the
female bone. These interesting models uncovered a wide spectrum of unexpected estrogen actions on bone in males, allowing the
formulation of an estrogen-centric theory useful to explain how sex steroids act on bone inmen.Most of the principal physiological
events that take place in the developing and mature male bone are now considered to be under the control of estrogen. Estrogen
determines the acceleration of bone elongation at puberty, epiphyseal closure, harmonic skeletal proportions, the achievement of
peak bone mass, and the maintenance of bone mass. Furthermore, it seems to crosstalk with androgen even in the determination
of bone size, a more androgen-dependent phenomenon. At puberty, epiphyseal closure and growth arrest occur when a critical
number of estrogens is reached. The same mechanism based on a critical threshold of serum estradiol seems to operate in men
during adulthood for bone mass maintenance via the modulation of bone formation and resorption in men.This threshold should
be better identified in-between the ranges of 15 and 25 pg/mL. Future basic and clinical research will optimize strategies for the
management of bone diseases related to estrogen deficiency in men.
1. Introduction
In the human male, testosterone (T) and estradiol (E
2
) are
the main circulating sex steroids acting on bone tissue. The
first is produced from the Leydig cells in the testis, while
the latter derives from the aromatization of the androgens by
means of the enzymatic complex of aromatase [1]. Aromatase
is a cytochrome P450 enzyme encoded by the CYP19A1 gene
that plays a key role in estrogen biosynthesis: it catalyzes the
conversion of Δ4-androstenedione into estrone and that of
T into E
2
[2, 3]. Aromatase is widely expressed in a large
number of tissues such as testis (Sertoli and Leydig cells),
ovary (granulosa cells and luteal corpus), brain (including
hypothalamus), hair follicles, and fibroblasts [2, 3]. Adipose
tissue also expresses aromatase and it constitutes an impor-
tant source of estrogens, especially in men [1–4]. In men,
in fact, E
2
is mainly produced by the testis and secondarily
by adipose tissue [2–4]. Biological actions of estrogens are
mediated by their receptor (ER) that belongs to the nuclear
receptors family, and, to date, two different ERs have been
identified: ER-𝛼 and ER-𝛽 [5]. A further nongenomic path-
way of estrogen action has been described probably involving
a plasma membrane interaction of the ER [6, 7].
Animal [8, 9] and human [10, 11] models of male con-
genital estrogen deficiency offered a new scenario useful
for better understanding estrogen effects on male bone
as well as several organs and tissues in men [12–14]. All
these physiological actions of estrogens in men remained
overlooked for a long time (see [13] for review). In the past,
estrogen was also erroneously considered indispensable for
blastocyst implantation [15] and congenital estrogen defects
are supposed to be incompatible with life [10, 11]. The
discovery of the first cases of congenital estrogen defects in
humans allowed understanding that aromatase deficiency is
due tomutations of the gene coding for the aromatase enzyme
complex, which leads to lack of both estrogen synthesis and
action, while estrogen resistance is due to mutations of the
genes coding for estrogen receptors and leads to resistance
to estrogen actions even in presence of circulating estrogens
[10, 11].
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This review will focus on the role of estrogens on human
male bone according to all skeletal physiological events that
occur in vivo in different life stages in men. The rise of T
and E
2
in men at puberty progressively exposes bone to sex
steroids, thus allowing them to act on the growing skeleton.
Sex steroids modify the way through which immature bone
develops in terms of size, structure, bone mineral density
(BMD), and proportions till the achievement of final skeletal
maturation. After the achievement of peak bone mass, estro-
gens continue to influence bone remodeling in adulthood, the
decline of circulating E
2
being directly correlated with bone
loss from adult to aging life.
2. Estrogen Effects on Bone from
Early to Late Puberty
Very low levels of estrogens circulate in the blood even in
male children during infancy, but their real physiological
significance is not known [16]. In prepubertal boys with a
genital Tanner stage 1, serum E
2
measured with the gold
standard liquid chromatography tandem mass spectrometry
(LC/MS/MS) starts to increase ranging from 0.5–1.0 to about
1.9 pg/mL in healthy controls and obese boys, respectively
[17, 18]. Considering the developing skeleton to not be under
the effects of estrogens before puberty in male fetuses and
children is a good simplification, even though this is a poorly
investigated field of research (Table 1).
The initial activation of the hypothalamic-pituitary-
gonadal axis in male children resulting in a progressive, slow
increase of sex steroids, including estrogens, characterizes the
peripubertal period [17–19]. Bone exposure to low concentra-
tions of estrogens leads to well-known estrogen-dependent
bone changes in males [20, 21].
2.1. Effects of Estrogens on Longitudinal Skeletal Growth.
The growth of long bones occurs at the growth plate, a
thin layer of cartilage that separates the epiphysis from the
metaphysis [22]. The growth plate consists of three distinct
layers of resting (stem cell-like), proliferative and hyper-
trophic chondrocytes [22, 23]. The concept that sex steroids
promote epiphyseal growth and maturation during puberty
in both sexes was a well-known issue in endocrinology since
the beginning of the last century [24–26]. This classical
endocrinological theory was based on a well-distinct action
of estrogen from androgen on bone. In fact, it was believed
that the former leads to growth plate maturation only in
women [27], while the latter leads to growth plate maturation
only in men [28, 29]. As a matter of fact, the failure of
epiphyseal closure and osteoporosis observed in adult men
with congenital hypogonadotropic hypogonadism or with
childhood onset severe T deficiency were both traditionally
ascribed to insufficient bone exposure to androgen at puberty
[30, 31]. Notwithstanding evidence on estrogen actions on
bonematuration inmen had become available since the 1980s
[32–34]; this viewpoint lasted since the beginning of the 1990s
when the idea that estrogen is the main sex steroid involved
in male bone maturation started to advance [35] thanks to
Table 1: Role of estrogens on male bone throughout lifespan.
Life stages Effects of estrogens on bone
Fetal life Poorly investigated/unknown
Infancy Poorly investigated/unknown
Puberty
Early
puberty
(detectable
but low E2)
Growth plate lengthening
Rapid advancement of bone age
Accelerated linear bone growth
Increase in height velocity (growth spurt)
Assurance of adequate target height attainment
Late
puberty
(high E2)
Thinning and progressive growth plate
disappearance before epiphyseal closure
Bone maturation
Advancement of skeletal maturation
Progression of bone age in late puberty
Epiphyseal fusion and growth arrest
Achievement of final height
Allowance of skeletal body proportions
Achievement of adequate peak bone mass
Bone size
Bone length
Periosteal bone apposition (crosstalk with
androgens)
Adulthood Maintenance of bone mass
Ageing Prevention of bone loss
E2: estradiol.
the description of the first cases of congenital defects of
estrogen synthesis or action [36–40].
The clinical phenotype presented by the unique male
patient described to date [36] with estrogen resistance was
very close to that ofmenwith aromatase deficiency [37, 40]. It
is characterized by tall stature, a history of continuous linear
growth into adulthood, unfused epiphyses, progressive genu
valgum, eunuchoid proportion of the skeleton, delayed bone
age, and osteoporosis. In 1997, Carani et al. [38] demonstrated
that transdermal E
2
replacement is effective in obtaining
complete epiphyseal closure, final skeletal maturation, the
arrest of growth in height, the increase in BMD, and peak
bonemass [10, 38].This result was subsequently replicated by
many other authors in all aromatase-deficient men described
so far [40–46]. On the other hand, six months of treatment
with high doses of T, given before the diagnosis of aromatase
deficiency in an attempt to arrest continuous linear growth,
had no effects on bone age in this patient [10, 38]. Besides,
E
2
treatment was not effective in the estrogen-resistant man,
as expected [36]. All these findings suggest that epiphyseal
closure is an estrogen-dependent phenomenon even inmales
and that androgens by themselves are not effective to ensure
a normal skeletal development during late pubertal stages
[10, 11, 21–23] (Table 1).
Later on, these findings opened the way to studies
investigating the role of estrogens on bone growth and
maturation not only in the context of congenital estrogen
defects but also in normal boys. Serum E
2
was found to
increase simultaneously with T levels during puberty in boys
and to correlate directly with chronological and skeletal age,
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Figure 1: Direct and indirect effects of increasing circulating estrogens and their depletion on the growth plate (a), and effects of estrogen
deprivation on bone elongation and epiphyseal status (b). AR: androgen receptor; E1: estrone; E
2
: estradiol; T: testosterone; ER-𝛼: estrogen
receptor alpha; ER-𝛽: estrogen receptor beta; GPR30: membranous-G-protein-coupled estrogen receptor.
height, weight, and pubertal stages, thus confirming the
crucial role of estrogens on bone physiology at puberty even
in the male [19, 21] (Table 1). In particular, estrogens seem
to have a dose-dependent effect on growth plates [21, 47]:
actually low doses of E
2
stimulate ulnar growth in boys
[33], while higher doses lead to an inhibition of this process
of growth [20]. Recently, circulating serum E
2
measured
by LC/MS/MS resulted directly related to both the genital
Tanner stage and the skeletal maturation in pubertal boys
[18]. In addition, serum E
2
was significantly higher and bone
agemore advanced in obese boys comparedwith healthy boys
at the same pubertal stage [48]. The excess of adipose tissue
in obese boys probably accounts for increased aromatization
of androgens into estrogens and for the advancement of
bone age due to the higher amounts of circulating estrogens
[18, 48]. This result is in line with the well-known gender
difference in the progression of skeletal maturation, which
is more rapid in women than in men and parallels gender
differences in theway serumE
2
increases throughout puberty
[19, 20, 33, 35]. At the beginning of puberty, when circu-
lating E
2
is low, the prevailing effect of E
2
consists in the
promotion of chondrocytes proliferation within the growth
plate, resulting in growth plate lengthening and accelerated
bone elongation (Figure 1) (Table 1). This corresponds to the
increase of height velocity occurring during pubertal growth
spurt that is postulated to be under estrogen control (Table 1)
[21, 40, 47]. As puberty goes on, the rise in serum T ensures
high E
2
circulating levels, typical of late puberty; E
2
inhibits
chondrocyte proliferation and stimulate chondrocyte differ-
entiation, thus inducing the progressive ossification of the
growth plate and its final disappearance (Figure 1). At present,
the amount of E
2
required for shifting from the increase in
length of the growth plate to its growth deceleration and final
closure of the growth plate line is not known in detail. Data
available in literature clearly show that no difference in serum
T is present between men with idiopathic hypogonadotropic
hypogonadism with fused epiphyses compared to those with
unfused epiphyses [30], but no data are available in literature
on serum estrogens in these rare conditions. This implies
that androgen is not involved in the process of shifting from
growth plate elongation to progressive growth plate thinning
and final disappearance (Table 1).
Based on the poor compliance of an aromatase-deficient
man, we tried to develop a dose-response relationship
between serum E
2
and radiological changes of the long bones
in terms of bone age [45]. Due to patient’s poor compliance,
serum E
2
remained below 20 pg/mL for a long time without
any change of bone age and growth plate appearance at X-ray
[45]. The closure of the epiphyses was obtained only several
months later when E
2
rose above 20 pg/mL and the patient
was taking the right dose of transdermal E
2
[45].This suggests
that serum E
2
above 20 pg/mL is necessary for epiphyseal
cartilage fusion [45] and that only in the case of severe
estrogen deficiency the epiphyses remain still open despite
the advancement of the chronological age (Figure 2). The
same results can be deduced from a recent study comparing
sex steroids, pubertal stage, and skeletal maturation between
obese and lean boys [17]. If boys at the end of puberty (with
a genital Tanner stage 5) are considered, bone age (of about
18 years on average) was greatly advanced and consistent
with fused epiphyses in obese boys with a mean serum E
2
clearly above 20 pg/mL (median 34.8 pg/mL,min–max: 25.6–
41.1 pg/mL), while bone age (of about 16 years on average)
was less advanced and consistent with still unfused epiphyses
in lean boys with a mean serum E
2
below 20 pg/mL (median
15.7 pg/mL, min–max: 13.2–21.0 pg/mL) [17].
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Figure 2: Proposed range for a critical serum estradiol threshold above which both skeletal maturation and mineralization can proceed in
an optimal way. E
2
: estradiol; BioE
2
: Bioavailable estradiol.
The molecular mechanism through which estrogens act
on the growth plate in vivo is still not known in detail, but
recently advance on this issue has been reached [22, 23].
Several convincing evidence suggests that the growth plate
width progressively decreases as a consequence of a process of
senescence involving the chondrocytes, mainly in the resting
zone [49]. How this senescence occurs and progresses is not
known, but severalmechanisms such as apoptosis, autophagy,
chondrocytes differentiation into osteoblasts, and hypoxia
have been proposed and are currently object of undergoing
investigation by basic scientists [23]. Certainly, estrogens
exert a strong effect on one or more of these pathways finally
resulting in the promotion of chondrocytes involution and in
the assurance of final epiphyseal closure followed by growth
arrest [21–23]. What is evident is that the number of both
chondrocytes and progenitor cells progressively decreases in
the resting zone of the growth plate and that estrogens accel-
erate this process, especially when they reach a critical level
[50]. Both ER-𝛼 and ER-𝛽 are expressed by human epiphy-
seal chondrocytes [51, 52]; moreover, the membranous-G-
protein-coupled estrogen receptor, namely, GPR30 [7], is also
expressed in the hypertrophic zone of human growth plate
[53]. Furthermore, the fact that aromatase is also expressed
by chondrocytes which are able to produce estrogens [54–56]
implies that both circulating and locally produced estrogens
are able to exert their actions within the growth plate via the
activation of all the available estrogen transduction signaling
pathways [22, 23]. Low levels of estrogens, similar to those
locally produced in vivo, are able to promote chondrocytes
proliferation and to protect them from cell death in vitro [57].
This mechanism might explain why low circulating and/or
locally produced estrogens enhance longitudinal growth
during early puberty. Conversely, the expression of the estro-
gen receptor GPR30 decreases dramatically during pubertal
progression in humans when circulating estrogens reach the
highest values typical of late puberty and longitudinal growth
decelerates up to cessation [53]. GPR30 is a good candidate
for explaining estrogen actions on growth plate since knock-
out mice in which this receptor is disrupted do not respond
to estrogen in terms of longitudinal growth deceleration and
cessation [58]. ER-𝛽, rather than ER-𝛼 [59], seems to be
mainly involved in the induction of growth plate fusion in
response to supraphysiological E
2
exposure [60]. However,
the complex interaction between estrogens and their recep-
tors within the growth plate remains to be elucidated in detail.
In the uniquemanwith estrogen resistance, epiphyseal fusion
did not occur at the expected time, despite high circulating
E
2
and normally functioning ER-𝛽 [36]. Besides, cultured
cells obtained from the bone biopsy of this patient did not
respond to estrogen exposure, differently fromwild type cells
[61, 62]. This issue is further complicated by the possible
crosstalk between ER-𝛼 and ER-𝛽. Theoretically, in fact, it is
possible that the residual truncated N-terminal fragment of
the disrupted ER-𝛼 may have acted as a negative inhibitor
of ER-𝛽 in this patient [62, 63], thus accounting for the
very delayed epiphyseal closure in this estrogen-resistantman
reached at the age of 35.5 years [61].
Other hormones are good candidates for explaining
growth plate proliferation, longitudinal bone growth, and
growth plate involution [23]. Among them, growth hormone
(GH) and insulin-like growth factor-1 (IGF-1) exert an
anabolic effect on bone and are necessary for longitudinal
bone growth and growth acceleration during infancy and
at the time of the growth spurt, respectively [23]. The role
of GH and IGF-1 on longitudinal bone growth and growth
spurt could be even indirect through the well-known ability
of estrogens to enhance GH and IGF-1 secretion, an event
that occurs during late puberty and that concurs to accelerate
growth during the pubertal spurt [10, 11, 35, 64] (Figure 1).
However, longitudinal bone growthmight occur and progress
also independently from the GH/IGF-1 status but at a lower
rate since men with aromatase deficiency continue to slowly
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increase their stature during adulthood, despite severe GH
deficiency [65]. Accordingly, GH response to GHRH plus
Arginine in four patients with aromatase deficiency was
significantly lower than that in normal subjects, both before
and after transdermal E
2
replacement therapy with E
2
[65].
In particular, E
2
replacement did not restore normal GH
secretion and IGF-1 that remained significantly lower than
normal age-matched controls [65]. The fact that estrogen
replacement treatment was effective on epiphyseal closure
and growth arrest in all patients with aromatase deficiency
[40], despite insufficient GH and IGF-1 production [65],
implies that GH and IGF-1 do not play a major role in the
process of growth plate closure in humans.These data suggest
that a tall stature (higher than the genetic target) may be
reached despite the coexistence of GH deficiency in these
patients. Even though we have no data about the GH-IGF1
axis in these patients during their childhood and puberty,
they were able to increase their stature during the first period
of E
2
treatment, soon before epiphyseal closure [40]. Besides,
when aromatase inhibitors are administered at puberty in
order to increase final height, usually a reduction of GH
and IGF1 levels is observed but a benefit on final height
is even obtained thanks to the epiphyseal fusion blockade
and a longer time available for growth [66, 67] (Figure 2).
All these data suggest that both longitudinal bone growth
and a slow progressive increase in height during adulthood
are possible even in presence of circulating GH and IGF-1
lower than normal on condition that epiphyseal growth plates
remains open. This condition might lead to the development
of tall stature [65]. Outside the context of these rare clinical
conditions that help to better know how sex steroids act on
the growing skeleton in healthy children and boys, GH and
IGF-1 remain very important physiological determinants of
growth during infancy and puberty since they ensure bone
elongation and a normal height velocity [64]. Accordingly,
GH deficiency represents one of the most important causes
of growth retardation and (if untreated) of final short stature.
Indeed, r-hGH replacement treatment is effective in restoring
a normal height velocity in children and boys with GH
deficiency [64].
2.2. Effects of Estrogens on Skeletal Proportions. In men,
estrogen at puberty modulates both growth and the increase
in stature in a fascinating way that allows accelerating the
growth of the appendicular skeleton for a brief period
only—characterized by low but detectable serum E
2
(early
puberty)—while preserving, at the same time, harmonic
skeletal proportions. Accordingly, the further increase of
serum estrogens triggers both epiphyseal closure and cessa-
tion of growth during mid-to-late puberty, thus avoiding the
development of an altered ratio between the appendicular
and the axial skeleton. Even though androgens alone are not
able to induce bonematuration, they exert direct and indirect
anabolic action on bone before, during, and after puberty
(Figure 1). In particular, during puberty, androgens probably
promote the continuous linear growth, especially at the level
of long bones as substantiated by the expression of androgen
receptors within the human growth plate [23, 68] and the
promotion of growth sustained by androgens through the
elongation of the growth plate, at least in rats [69] (Figure 1).
Disproportional growth of long bones leads to eunuchoid
proportions of the skeleton characterized by the prevailing
length of arms and legs over the spine. Usually the eunuchoid
skeleton is defined by the finding of an abnormal upper to
lower segment ratio (<0.88) and by the predominance of the
arm span over the patient’s height (ratio > 1) [40, 47, 70].
Menwith estrogen deficiency have a prolonged time available
for linear growth thanks to a still open growth plate and
they exhibit eunuchoid body proportions (Figure 1) [40, 47],
whichworsen if they are not treatedwith exogenous estrogens
[43]. Conversely, if the onset of E
2
treatment starts at the
proper time, during early puberty, body proportions are unaf-
fected in males with aromatase [41]. This evidence highlights
the concept that estrogen rather than androgen is necessary
also for a harmonic skeletal growth (Figure 1) (Table 2). As
a matter of fact, normal skeletal proportions are found in
patients affected by complete androgens insensitivity syn-
drome (CAIS) where normal-to-high E
2
serum levels allow
epiphyseal closure at the right timing, despite the absence of
androgen action [71, 72]. The adult height of patients with
CAIS usually corresponds, in fact, to both the calculated
target and mean height of men rather than females standard
[72]. All clinical conditions that lead to severe T deficiency
before the completion of puberty and that are characterized
by eunuchoid proportions of the skeleton [70] share the
same mechanism of severe estrogen deficiency secondary to
hypogonadism [73] (Figure 1). Thus, relative severe estrogen
deficiency secondary to insufficient androgen production
leads to eunuchoid body proportions in prepubertal male
hypogonadism [70, 73], 17,20-lyase deficiency and combined
17𝛼-hydroxylase and 17,20-lyase deficiency [40, 47].
2.3. Effects of Estrogens on Bone Mass Accrual and Attainment
of Peak Bone Mass. The peak of bone mass (bone growth
and BMD increase during childhood and young adulthood)
determines the total amount of bone mineralized tissue
available during adulthood till aging [74, 75]. Once the peak
of bone mass is achieved during puberty and early adulthood
(before the age of about 30 years), the bone becomes unable
to reach further significant bone mass accrual. Thus, the
bone mass remains stable or decreases on the basis of the
balance between bone formation and resorption [74, 75].
The achievement of peak bone mass is prompted by the rise
in sex steroids at puberty. Even this process was previously
supposed to be under the control of estrogens in females
and of androgens in males [10, 11, 76]. All the events that
can negatively interfere with the achievement of peak bone
mass predispose to the development of osteoporosis later in
life in both sexes [74, 75]. Among them, physiological or
pathological conditions that determine sex steroid deficiency
result in impaired peak of bone mass, such as in the case of
prepubertal hypogonadism or delayed puberty in boys and
anorexia nervosa in girls [30, 31, 75].
Probably androgens alone are not sufficient for the
achievement of a normal BMD and an optimal peak of
bone mass since severe osteoporosis was reported in all
6 International Journal of Endocrinology
Men
Women
T 
Aging
30 years 60 years 90 years 
E2
+ E2T
+ E2T
Figure 3: Schematic representation of the role of estrogen and androgen bone size according to gender. The effects of sex steroids on cortical
and trabecular bone are represented. Bone size is reached in late puberty and early adulthood as depicted at the left of the panel where the
effect of each sex steroid and their sum are shown according to gender. In men, the combined action of both T and E
2
led to greater bone size
and cortical thickness than in women. The prevailing effect of E
2
is consistent with higher endosteal bone formation in women. Bone loss
during aging occurs in a different fashion between man and women and is subordinate to the baseline conditions. Women lose more bone on
the endosteal surface and in the trabecular portion of bone, while men lose mainly bone mass in the cortical bone (right side of the panel).
E
2
: estradiol, T: testosterone; modified in part from figures published in [75, 77].
young adults with estrogen resistance [36] or aromatase
deficiency [38–40]. The importance of estrogens for the
acquisition of peak bone mass during puberty is evident by
the results obtained from both human [47] and mice models
[8] of estrogen deficiency (Table 1). Several mice models of
estrogen deficiency have been generated and all confirmed
that even in rodent estrogens mediate most of the actions
exerted on bone by androgens [8, 77, 78]. In particular, the
knock-out of the ER-𝛼 in male mice leads to the increase
of trabecular bone, the reduction of cortical bone, and the
decrease of longitudinal bone growth, while the knock-out of
the ER-𝛽 does not impact cortical and trabecular bone [78].
All these data reinforce the importance of ER-𝛼 in male bone
homeostasis [78, 79]. Studies performed on animal models,
however, do not allow transposing all the results to human
male bone physiology due to substantial differences in sex
steroid and bone physiology among species [77]. In rodent, in
fact, circulating estrogens are very low and often undetectable
so that the intracrine role of estrogens prevails over that of
serum E
2
[77]. Furthermore, in rodent, sex steroids do not
bind sex hormone binding globulin, and finally the process
of bone maturation is different in rodent due to the absence
of epiphyseal cartilage [77, 78]. The idea that estrogen is the
main sex steroid involved in the acquisition of peak bone
mass has been confirmed by other several data available in
literature from rare models of sex steroids deficiency and
from studies on pubertal boys. Inmen with CAIS, the peak of
bone mass is only in part reduced, with intermediate values
in-between those of male and female subjects [72], while
men with aromatase excess syndrome display an increased
BMD at the end of puberty due to high circulating estrogens
throughout puberty [80]. In addition, outside the context
of rare syndromes of sex steroids deficiency, several other
studies involving pubertal boys clearly demonstrate that
peak bone mass is under the control of estrogen even in men
(Table 1) [17, 18, 48, 81–83]. During puberty, E
2
leads to the
increase of bone mass mainly by increasing BMD, especially
at the level of cortical bone whereas T contributes to increase
the bone size, a phenomenon that is mainly mediated by the
mechanical load exerted on bone by the increasing muscle
mass [18]. As far as bone geometry is concerned, E
2
seems
to be negatively associated to endosteal circumference [18]
and seems to positively influence the increase of cortical
thickness both at the level of radius and tibia [18]. Thus,
both estrogens and androgens seem to be necessary for
normal bone mass accrual during puberty. Androgens
limit endosteal expansion and estrogens ensure adequate
periosteal bone expansion [18] (Figure 3). The final result
is a bone size greater than that of the female counterpart.
Compared to females, male bone has, in fact, a larger cortical
portion due to greater periosteal apposition and a larger
endosteal circumference due to reduced endosteal apposition
[18, 75, 77] (Figure 3). As a result of all these events, final peak
bone mass is determined by the increase of BMD during
puberty and early adulthood plus the remaining more slow
bone accrual that continues till the 3rd decade of life and
accounts for about 20% of peak bone mass [83].
3. Estrogen Effects on Bone during Adulthood
3.1. Estrogen and the Maintenance of BMD. In order to
maintain a biomechanically efficient bone, the skeleton needs
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to continuously remodel and repair the microcracks that
develop both in the trabecular and cortical bone during
lifetime [75, 83]. This process of remodeling occurs in
basic multicellular units (BMUs) which include osteoclasts,
osteoblasts, and osteocytes [84] that act altogether by cou-
pling bone resorption and bone formation. The balance
between bone formation and bone resorption determines the
maintenance (if the two processes balance out the amount of
bone mass) or the loss (in the case of resorption higher than
formation) of bone mass in men [74, 84]. Sex steroids exert a
direct action on the BMUs and can regulate, at least in part,
bone remodeling [83–85]. While this effect was traditionally
ascribed to estrogens in females, in the last 20 years, several
studies progressively have disclosed the sameoutcome inmen
[62, 74, 75, 83–85].
Evidence from basic research had already demonstrated a
direct estrogen action on bone cells andmore data, especially
on biomolecular mechanisms of action, have been progres-
sively obtained till now [84, 85]. In particular, estrogens
inhibit the apoptosis of osteocytes both in trabecular and
cortical bone [84, 86].They reduce bone resorption bymeans
of both direct and indirect effects on osteoclasts [84] and
act on osteoblasts, by inhibiting their apoptosis [84, 87]. In
general, estrogen regulates bone remodeling by (i) inhibiting
the activation of bone remodeling and the initiation of new
BMUs; (ii) reducing the number and activity of osteoclasts
(i.e., inhibition of their differentiation and promotion of
apoptosis) and bone resorption; and (iii) increasing the
number and the activity of osteoblasts (i.e., promotion of their
commitment and differentiation and inhibition of apoptosis)
and bone formation [77, 79, 84, 88]. For all these reasons,
bone loss in man is mainly related to relative estrogen
deficiency [74, 77, 84, 88, 89], while androgens have a minor
role [74, 75, 83, 84]. Accordingly, the net effect of androgens
per se on bone mass in vivo is quite poor. DHT, for example,
is not able to increase BMD in patients with benign prostate
hyperplasia [90]. In these patients, lumbar BMD decreases
of about 1.5% after 24 months of treatment as a result of the
net compensation between the poor anabolic effects of high
circulating DHT and its prevalent negative effect on BMD.
The latter is due to the inhibition of gonadotropin secretion
and the reduction of sera T and E
2
, with a reduced estrogen
action on bone [90].
Several studies investigated the relationship between
estrogen and BMD in men through different types of study
design and all unequivocally demonstrate that estrogen
action on the male bone is more determinant than androgen
action [74, 75, 77, 83, 84, 89]. A normal BMD is observed in
male patients with CAIS [72]. Serum E
2
and relative estrogen
deficiency resulted associated with altered bone turnover
markers [91], BMD [92–98], and fracture risk [99–102]. Most
of these findings were confirmed by large epidemiological
longitudinal studies [92, 94, 96–101]. Altogether, these studies
provide evidence that E
2
is a better predictor of male bone
health than T.
In addition, E
2
administered to male to female transsex-
uals [103–105] or to men with prostate cancer [106] signifi-
cantly increases BMD, despite endogenous serum T suppres-
sion. Otherwise, aromatase inhibitors lead to alterations of
bone turnover markers [107] and impairment of BMD [108].
Finally, genetic studies revealed an association between ERs
[109, 110] or aromatase enzyme [111, 112] polymorphisms with
decreased BMD in men.
Exogenous E
2
acts in a dose-dependent fashion on male
bone since it restores a normal BMD in aromatase-deficient
men given at a dose that ensures stable serum E
2
levels
within the normal male range [40, 113, 114]. A daily dose
of E
2
lower than 20𝜇g is usually unable to keep serum E
2
within the normal range in these patients. The result is
BMD worsening or failure in restoring a normal BMD in
men previously treated with higher doses [113] and in naive
patients [45], respectively. Similarly, in adult men without
genetic diseases involving estrogen pathways, E
2
seems to be
protective for bone but only when serum levels are above a
critical threshold [102]. In cohort studies, this threshold has
been settled in-between 15 and 20 pg/mL [115]. By studying
the effects of estrogen treatment in an aromatase-deficient
man [45], this threshold has been more precisely determined
as being around 16 pg/mL (Figure 2).This value has been also
confirmed by studies on fracture risk in older men (Figure 2)
[102]. Recently Khosla et al. stated that a serum E
2
level
at least above 25 pg/mL is certainly protective for bone in
men (Figure 2) [88]. All these data suggest that serum E
2
levels of 20 pg/mL or above are needed for optimal skeletal
maturation and achievement of optimal peak bone mass
[116]. This threshold is very close to that required also for the
epiphyseal closure (Figure 2) [45, 116].
The concept that estrogens act on bone only when a
specific amount is reached is well established, whereas the
precise threshold value remains to be settled. Differences in
study design and overall in methods used for estrogen assays
might explain the discrepancy between values obtained from
different studies. In the future, the wide use of the gold
standard methods (LC/MS/MS) for the measurement of
estrogen in serum will provide more reliable information on
the exact threshold value: the latter will probably fall within
the suggested range of 15–25 pg/mL (Figure 2). Furthermore,
future studies will be of help in disclosing if individual,
genetic differences in estrogen sensitivity might influence the
amount of estrogens needed for a full estrogen action on
bone.
In conclusion, clinical and basic research demonstrate
that E
2
is the main sex steroid required for bone homeostasis
in men [74, 77, 83, 84, 88, 89].
3.2. Estrogens and Bone Size. Bone size exhibits evident
gender differences that are ascribed mainly to sex steroids
actions on bone [83, 117, 118]. Estrogen controls the final
length of long bones by acting on epiphyseal closure (see
the paragraph above for details). The length of long bones
is greater in men than in women. This could be once
again the effect of the more rapid increase of estrogens at
puberty in women which is responsible for an anticipated
epiphyseal closure and growth cessation [17, 18, 48]. Actually,
bone mass and strength are greater in men than in women;
probably these differences are due to different length and
bone structure among the two sexes (Figure 3) [76]. Bone
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size, in fact, is larger in men than in women mostly as a
consequence of awiderwidth of bone, especially of its cortical
portion (Figure 3) [75, 77, 115, 118, 119]. The enlargement
of the periosteum involves the appendicular skeleton, and
it mainly occurs from puberty to the 3rd decade of life
[75]. In men, this process leads to continuous increase of
the cortical thickness (Figure 3) [119–121]. Conversely, in
females, this process ceases earlier and does not continue
during young adulthood [119–121]. In addition, the very
high amount of estrogen in women is responsible mainly
for endosteal bone formation. The final result is that adult
females have smaller cortical bone portion and a shorter
endosteal circumference than males (Figure 3) [75, 77, 115–
121].
It has been suggested that the different levels of circulating
androgens between the two sexes can explain this sexual
dimorphism in bone structure. As the final pathways of
sex steroids actions in bone are the same in the two sexes,
this sexual dimorphism in bone size probably comes from
indirect actions of sex steroids on tissues different from bone.
With this in view, a possible role of T in establishing bone
size can be explained by sex differences in muscle mass [122]
which start to appear at the time of puberty [48].Musclemass
is androgen-dependent [122] and greater muscle mass can
exert greater mechanical action on bone [123], thus resulting
in increased bone size and bone mass [75]. Obese boys, for
example, have larger muscle size and larger bones in the
legs if compared with lean boys at the same pubertal stage
[48]. Furthermore, whenT is administered to ovariectomized
female-to-male transsexuals, both muscle and skeletal mass
change and the final musculoskeletal system resembles that
of the male counterpart [124].
The old view postulated that androgen stimulates
periosteal expansion in men, whereas estrogen inhibits
periosteal apposition in women. The finding of significant
periosteal expansion prompted by estrogen treatment in a
boy with aromatase deficiency [41] suggests a more complex
cross-talk between these two hormones within the bone
periosteal surface [125]. Estrogens might exert a permissive
action on androgens, thus facilitating and promoting their
anabolic effect on the periosteum; this event does not take
place or is minimized when estrogens are lacking or are
below the normal range (Figure 3) [125]. Lesson from rare
models of estrogen or androgen deficiency seems to confirm
this hypothesis. In fact, bone size has a female appearance in
XY patients with CAIS [126, 127]. Accordingly, Vandenput
and colleagues [128] studied the role of the androgen receptor
in the skeletal homeostasis of androgen-resistant, testicular
feminized, male mice and observed that bone size and
bone formation at the periosteal surface depend also on a
functional androgen receptor. The mechanism consists in a
permissive estrogen role on androgens and seems to operate
also on trabecular bone homeostasis [114]. This permissive
estrogen action, however, needs to be confirmed and better
clarified on a molecular point of view.
In conclusion, the role of each sex steroid on bone size and
on gender difference is a complex phenomenon that involves
also other endocrine systems like the GH/IGF-1 and that
needs still to be better clarified.
4. Estrogen Effects on Bone While Aging
The progressive decline of T that usually occurs with advanc-
ing age might result in a corresponding decrease of circu-
lating estrogens in men [74, 98, 102, 129]. Relative estrogen
deficiency in elderlymenwith lowT is common and has been
clearly demonstrated in most of the longitudinal studies on
sex steroids in older men [98, 101, 102, 129].There is, however,
the possibility that both androgens and estrogens do not
decline with advancing age, especially in older men in a good
health status [130]. A mild-to-severe reduction of circulating
T in older men who develop age-related hypogonadism
is directly responsible for bone loss, but the concomitant
decrease of circulating E
2
has a main impact on bone health
[14, 129]. In older men, the 70–85% of the decrease in
BMD related to sex steroids decline is imputable to estrogen
deficiency while only the remaining 15–30% is imputable to
androgens [74, 84, 91]. Relative estrogen deficiency causes a
decrease of both trabecular [83, 88, 89, 98–101] and cortical
[131] bone in older men, leading to a bone structure that
strongly resembles that of young aromatase-deficient men
[74, 132]. Bone size, in fact, decreases at least in part as
an effect of contraction of the cortical portion of the bone
[75, 77, 116, 117]. However, the main changes related to
aging that occur in male bone regard the bone structure. In
particular, cortical porosity increases with age [75, 77, 131]
while BMD decreases [75, 77, 83, 84]. BMD changes are due
to the reduction of trabecular bone volume that is sustained
by the thinning of the trabeculae rather than a reduction
of their number, the latter being a mechanism involved in
female bone aging [75, 77, 83, 84]. Another mechanism
involved in male bone aging is endosteal resorption. In men,
endocortical resorption is less pronounced than in women
but substantially contributes to decreasing cortical cross-
sectional area and consequently bone strength (Figure 3) [74,
75, 77, 83, 84, 88, 89, 98–101, 131].
To what extent the decrease in BMD due to relative
estrogen deficiency contributes to the incidence of fractures
in aging men with late-onset hypogonadism is still not com-
pletely clear. Men with congenital estrogen deficiency were
classically considered at risk to develop fracture, but only
recently a history of pathological fractures of the forearmafter
minimal trauma has been observed in a man with aromatase
deficiency [46]. Long-term outcome concerning fractures in
those rare male patients remains still not available [40]. Data
obtained from older men demonstrate that E
2
is inversely
associated with BMD [92–98] and seems to predict fractures
better than T [99–102]. However, not all the older men with
low serum T develop relative estrogen deficiency [98, 102]
and probably onlymen with concomitant low serum E
2
are at
high risk of fracture. Individual differences in both aromatase
activity and expression probably might explain why in the
presence of low serum T only a subgroup of men with
late-onset hypogonadism has relative estrogen deficiency
(Table 2) [74]. However, well designed studies aimed at
exploring this hypothesis are still lacking. Among men with
low serum T, those with concomitant estrogen deficiency
should be considered to be at high risk of osteoporotic frac-
tures (Table 2), especially when serum E
2
is below 25 pg/mL
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Table 2: Risk of osteoporosis and fractures along with clinical
manifestations according to estrogen status in elderly men.
Elderly men with late onset hypogonadism
Estrogenic
status
Relative estrogen
deficiency
(less functioning
aromatase)
Normal circulating
estrogens
(normal functioning
aromatase)
Clinical
phenotype
Low serum E2 Normal serum E2
Normal E2/T ratio Impaired E2/T ratio
Highest gonadotropins Less increasedgonadotropins
Severely impaired BMD Normal to moderateBMD decrease
Osteoporosis Osteopenia
Risk of developing
gynecomastia
Fracture risk High Low
E2: estradiol; T: testosterone; BMD: bone mineral density.
(Figure 2). T deficiency further contributes to increasing the
risk of fractures in these patients. Accordingly, muscle mass
reduction that is related to androgen depletion [122] worsens
BMD [123] and increases the risk of falling in elderly men
[115, 133].
In conclusion, elderly male might present relative estro-
gen deficiency that may be implied in several age-related
conditions [14] that can affect and worsen quality of life,
including bone loss.
5. Areas of Uncertainties
Even though now the crucial role of estrogen on bone home-
ostasis is well established many uncertainties still remain to
be clarified both in the field of basic and clinical research as
well as in the field of translational endocrinology.
5.1. The Research Corner. Estrogen effect on male skeleton
during fetal life and childhood has not yet been investigated
while preliminary data during pubertal development are
becoming available [16–18, 48] (Table 1). Furthermore, data
on the effects of estrogen deprivation on the growing skeleton
in men with congenital estrogen deficiency are scanty [40].
The exactmolecularmechanism of estrogen action on the
process of skeletal maturation remains to be established in
details. We still do not know whether estrogens are directly
involved in epiphyseal closure or whether their effect is
mediated by a more complex hormonal network (endocrine
and/or paracrine) including cytokines and growth factors.
The lack of animal models useful to study the pathophysiol-
ogy of the growth plate complicates the advancements on this
issue. The models available present several limitations. The
physiology of growth plate and the process of ossification of
long bones in rodents are very different from those of humans
[22, 23, 60].The rabbit is closer to human but presents several
significant differences [22, 23, 49–51].
While the role of circulating estrogens on bone matu-
ration and accrual has been clarified, the contribution of
intracrine estrogen production is unknown. Furthermore,
the other endocrine systems and growth factors recruited
by estrogen and having an important role within the bone
remains to be identified.
The effects on bone of selective estrogen receptor mod-
ulators (SERMs) remain doubtful due to conflicting results
available in the literature. Raloxifene, a SERM with a proven
estrogen agonist action on bone with estrogen antagonist
actions on other tissues, was not effective in inducing
epiphyseal closure in an aromatase-deficient man after 24
months of treatment [134]. Conversely, tamoxifen, another
SERM with agonist action on bone, induces permanent
growth arrest through the apoptosis of chondrocytes in rats
[135]. Raloxifene, however, is able to increase BMD both
in aromatase-deficient men [134] and in men with prostate
cancer [136, 137].
5.2. The Clinical Corner. About 20 years of research in the
field of estrogen on bone did not lead to significant changes
in clinical practice. Therapeutic strategies aiming to target
estrogens for inducing changes in the male bone include
aromatase inhibitors for the treatment of short stature in
children and adolescents and estrogen-like compound for
osteoporosis in adult and elderly men. None of these strate-
gies, however, reached the expected results and nowadays
they remain confined to the clinical research area without any
real impact and extensive use in clinical practice.
Aromatase inhibitors are effective in increasing final
height [67, 138] but the results in terms of centimeters
reached are less than those expected if the epiphyseal closure
is completely blocked. Aromatase inhibitors decelerate the
advancement of bone age [67, 138], but the latter is not com-
pletely blocked as it happens in aromatase-deficient men [67,
138]. Probably even themost potent 3rd generation aromatase
inhibitors are not able to completely block the enzyme [139]
or, alternatively, after a first period of successful blockade,
a phenomenon of escape might occur since serum E
2
tends
to progressively increase even though at a lower rate than
in the placebo group [138]. This probably also accounts for
the lack of reported undesired effects, such as osteoporosis,
which would be expected in the case of complete blockade of
the enzyme. Recently, however, Hero et al. reported vertebral
deformities in boys treated with letrozole [140]. It is not clear
whether severe prepubertal and pubertal estrogen deficiency
might lead to skeletal deformities. Sporadic skeletal deformi-
ties (i.e., kyphosis and bilateral femoral osteonecrosis) have
been observed inmenwith estrogen deficiency, but the cause-
effect relationship with estrogen deprivation needs to be
confirmed [40]. Finally, further data from clinical trials are
required in order to obtain final data on safety for the use of
aromatase inhibitors in boys since theoretically more adverse
events are expected to occur [141, 142].
The most critical issue in clinical practice is the poor
reliability of the commercially available assays.Their accuracy
and reproducibility are insufficient especially in the low range
of serum E
2
typical of men [40, 74, 143]. The development
of new techniques that are considered to be the gold
standard, such as LC/MS/MS, is providing precise standard
methodologies useful for serum estrogenmeasurement [143].
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In the last years, these new methodologies are becoming
even more widespread among clinical laboratories since they
could be cost and time saving, especially in laboratories that
perform a great number of assays per day. At present, serum
E
2
is not currently part of the work-up used for the clinical
diagnosis and management of male osteoporosis. Several
authors, however, are going to introduce this biochemical test
in the clinic when the lab outcomes are accurate. Thus, we
will be able to improve our knowledge about the real critical
amount of circulating estrogens required to ensure bone
health.
Osteoporosis still remains an overlooked and
undermanaged disease in older men [74, 144], while all the
advancements in the field of estrogen deficiency and bone did
not result in practical, significant changes in the approach to
male osteoporosis. All these uncertainties reflect the wide dif-
ferences among physicians approaching estrogen deficiency
in the context of osteoporosis in older men [74, 144] as well
as all the difficulties in identifying a way to physiologically
increase serum E
2
without concomitantly impairing
androgen production. The only practicable way remains T
therapy that is able to restore both normal sera T and E
2
with
consequent beneficial effects on bone in the presence of a
normal functioning enzyme [144]. However, T replacement
treatment should be considered only after careful evaluation
of potential benefits and disadvantages since it could be
harmful especially in older men who are not in a good health
status [145–147]. It should be remarked that T treatment is
currently not a treatment of choice for male osteoporosis
[148].
6. Conclusions
Several evidence support the view that estrogens are themain
sex steroids involved in processes such as bone maturation,
bone mass accrual, and epiphyseal closure in men. Estrogen
actions on bone, especially on bone maturation, remained
quite unaltered among both gender and species during
evolution, thus suggesting a high degree of conservative
functions for estrogen that are also confirmed by the high
degree of homologies of the aromatase enzyme. Conversely,
estrogen actions on other tissues and organs are determinant
in ensuring gender differences (e.g., primary and secondary
sexual characteristics) and in promoting sexual divergence
between the two sexes during evolution. The existence of a
threshold level for serum E
2
that is necessary for ensuring
skeletal maturation and adequate bone size and BMD con-
firms how complex the way estrogen acts on bone in men is.
All these evidence contribute to make the issue of estrogen
action on bone a fascinating one in the field of both basic
and experimental research and encourage researches in order
to find new strategies for the management and treatment of
bone diseases related to estrogen deficiency.
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